Ultragenyx Pharmaceutical Inc. (RARE) Comparison with companies in other sectors?

Ultragenyx Pharmaceutical Inc. has a share price of 94.54M. You can analyze Ultragenyx Pharmaceutical Inc. (RARE) competitors across different market sectors through stock heatmaps.

What are RARE's NET and operating margins?

Ultragenyx Pharmaceutical Inc. (RARE) operating margin is around -0.87, and net profit margin is approximately -0.93 as of the latest reports.

In what way does RARE's earnings per share (EPS) trend reflect its financial momentum?

Ultragenyx Pharmaceutical Inc. (RARE) EPS is -5.83 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Ultragenyx Pharmaceutical Inc. is -5.32, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Ultragenyx Pharmaceutical Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Ultragenyx Pharmaceutical Inc. like P/E which is -5.45, P/B which is 20.75, and PEG which is -0.75. Compare them with sector averages to evaluate if the stock is priced fairly.

Ultragenyx Pharmaceutical Inc.

RARE•NASDAQ

Healthcare

Biotechnology

$30.37

$-11.07(-26.71%)

Fundamental Analysis of Ultragenyx Pharmaceutical Inc. (RARE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-5.83

P/E Ratio

-5.32

ROE

-1.86%

Net Margin

-0.93%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$2.93B

Shares OutstandingTotal number of shares issued

$94.54M

Book Value/ShareNet worth per share

$1.57

Revenue/ShareAnnual revenue per share

$6.13

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-5.83

Net MarginNet income as percentage of revenue

-93.04%

Operating MarginOperating income as percentage of revenue

-86.94%

ROEReturn on shareholders' equity

-186.49%

ROAReturn on total assets

-41.89%

ROCEReturn on capital employed

-50.34%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-4.29

Cash/ShareCash and equivalents per share

$5.13

FCF YieldFree cash flow as percentage of market cap

-13.86%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RAREFinancial Ratios Analysis details for RARE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RARESector Benchmarking details for RARE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Ultragenyx Pharmaceutical Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Ultragenyx Pharmaceutical Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Ultragenyx Pharmaceutical Inc.'s unique business strengths and challenges.

Key Financial Metrics for Ultragenyx Pharmaceutical Inc.

For Ultragenyx Pharmaceutical Inc., essential financial indicators include EPS -5.83, PE -5.32, and ROE -1.86. These key ratios reveal insights into Ultragenyx Pharmaceutical Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Ultragenyx Pharmaceutical Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Ultragenyx Pharmaceutical Inc.

Metrics like Net Margin -93.04% and ROA -41.89% shed light on how well Ultragenyx Pharmaceutical Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Ultragenyx Pharmaceutical Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Ultragenyx Pharmaceutical Inc.

Using ratios such as P/B Ratio 20.75 and PEG Ratio -0.75, investors can assess whether Ultragenyx Pharmaceutical Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Ultragenyx Pharmaceutical Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Ultragenyx Pharmaceutical Inc.

Financial health indicators, such as Debt/Equity Ratio 0.27 and Cash Flow $-4.29, provide a snapshot of Ultragenyx Pharmaceutical Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Ultragenyx Pharmaceutical Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Ultragenyx Pharmaceutical Inc.

Investing in Ultragenyx Pharmaceutical Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Ultragenyx Pharmaceutical Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;